Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy

NCT01067222 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

110

Enrollment

OTHER

Sponsor class

Conditions

Narcolepsy
Excessive Daytime Sleepiness
Cataplexy
Sleep Disorders

Interventions

DRUG: BF2.649
DRUG: Modafinil
DRUG: Placebo

Sponsor

Bioprojet